Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series.
作者信息
Hackley Madison, Loesch Amanda, Brownstone Nicholas, Hsu Sylvia
机构信息
Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Temple University Health System, Inc., Philadelphia, PA, United States.
出版信息
Front Med (Lausanne). 2023 Oct 30;10:1283313. doi: 10.3389/fmed.2023.1283313. eCollection 2023.
Abstract
摘要
相似文献
1
Commentary: Successful treatment of refractory palmoplantar pustular psoriasis with apremilast: a case series.评论：阿普斯特成功治疗难治性掌跖脓疱型银屑病：病例系列
Front Med (Lausanne). 2023 Oct 30;10:1283313. doi: 10.3389/fmed.2023.1283313. eCollection 2023.
2
Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series.阿普司特成功治疗难治性掌跖脓疱型银屑病：病例系列
Front Med (Lausanne). 2020 Oct 15;7:543944. doi: 10.3389/fmed.2020.543944. eCollection 2020.
3
Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.阿普米拉斯单药治疗掌跖脓疱病：三例报告。
SAGE Open Med Case Rep. 2021 Aug 11;9:2050313X211034926. doi: 10.1177/2050313X211034926. eCollection 2021.
4
Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.阿普司特治疗掌跖银屑病和掌跖脓疱病：一项系统评价和荟萃分析。
Dermatol Ther (Heidelb). 2023 Feb;13(2):437-451. doi: 10.1007/s13555-022-00877-w. Epub 2023 Jan 6.
5
Refractory palmoplantar pustulosis succesfully treated with apremilast.阿普斯特成功治疗难治性掌跖脓疱病。
Dermatol Ther. 2020 Mar;33(2):e13230. doi: 10.1111/dth.13230. Epub 2020 Feb 9.
6
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.生物疗法治疗掌跖银屑病和掌跖脓疱病的疗效：一项系统评价
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.
7
Principal Component Analysis to Differentiate Patients with Palmoplantar Pustulosis from Those with Palmoplantar Pustular Psoriasis.主成分分析用于区分掌跖脓疱病患者与掌跖脓疱型银屑病患者。
Ann Dermatol. 2022 Feb;34(1):7-13. doi: 10.5021/ad.2022.34.1.7. Epub 2022 Jan 27.
8
Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.掌跖斑块状银屑病和掌跖脓疱病患者的临床和流行病学比较：一项病例系列研究。
Br J Dermatol. 2013 Jun;168(6):1243-51. doi: 10.1111/bjd.12223.
9
Characteristics and Burdens of Disease in Patients from Beijing with Generalized Pustular Psoriasis and Palmoplantar Pustulosis: Multicenter Retrospective Cohort Study Using a Regional Database.北京泛发性脓疱型银屑病和掌跖脓疱病患者的疾病特征和负担：使用区域数据库的多中心回顾性队列研究。
Am J Clin Dermatol. 2023 Nov;24(6):991-1002. doi: 10.1007/s40257-023-00807-2. Epub 2023 Jun 29.
10
Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.司库奇尤单抗成功治疗与银屑病关节炎相关的顽固性环状脓疱型银屑病。
JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep.
本文引用的文献
1
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.阿普米司特治疗日本掌跖脓疱病患者的疗效和安全性：来自一项 2 期、随机、安慰剂对照研究的结果。
Am J Clin Dermatol. 2023 Sep;24(5):837-847. doi: 10.1007/s40257-023-00788-2. Epub 2023 May 26.
2
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.在 Effisayil 1 研究中，spesolimab 治疗泛发性脓疱型银屑病发作的疗效在预先指定的患者亚组中。
Exp Dermatol. 2023 Aug;32(8):1279-1283. doi: 10.1111/exd.14824. Epub 2023 May 4.
3
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.依斯巴汀单抗，一种抗白细胞介素-36 受体单克隆抗体，用于治疗泛发性脓疱型银屑病：来自 II 期 GALLOP 试验的结果。
Br J Dermatol. 2023 Jul 17;189(2):161-169. doi: 10.1093/bjd/ljad083.
4
Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.阿普司特治疗掌跖银屑病和掌跖脓疱病：一项系统评价和荟萃分析。
Dermatol Ther (Heidelb). 2023 Feb;13(2):437-451. doi: 10.1007/s13555-022-00877-w. Epub 2023 Jan 6.
5
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.德瓦鲁单抗对比安慰剂和阿普米司特治疗中重度斑块状银屑病：为期 52 周、随机、双盲、III 期方案 fOr 评估 TYK2 抑制剂银屑病二次试验的疗效和安全性结果。
J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14.
6
Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series.阿普司特成功治疗难治性掌跖脓疱型银屑病：病例系列
Front Med (Lausanne). 2020 Oct 15;7:543944. doi: 10.3389/fmed.2020.543944. eCollection 2020.
Zotero 插件